Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.73 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.73 |
| ▸ | PI4KA | P42356 | 3/20 | 0.67 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.67 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.67 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.67 |
| ▸ | NSD3 | Q9BZ95 | 5/20 | 0.57 |
| ▸ | NSD2 | O96028 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | ADCY5 | O95622 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11222112 | 0.91 | ADORA2A (0.80) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL2638945 | 0.90 | ADORA2A (0.74) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL5015473 | 0.88 | ADORA2A (0.72) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL5033136 | 0.86 | ADORA2A (0.73) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL984944 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL218588 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL16762626 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL15841807 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL2638100 | 0.84 | ADORA2A (0.71) | ADORA2AADORA1ADORA2BPI4KAPI4K2B | |
| SCHEMBL29459142 | 0.84 | ADORA2A (1.00) | ADORA2AADORA1ADORA2BPI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | claimed |
| JP-4603265-B2 | — | — | 2010-12-22 | — | — | JP | claimed |
| US-6995143-B2 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2006-02-07 | — | — | US | claimed |
| EP-1478653-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2004-11-24 | — | — | EP | claimed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | claimed |
| WO-2003072588-A1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2003-09-04 | — | — | WO | claimed |
| CN-114384756-A | Resin composition, toner for developing electrostatic image, image forming method, photosensitive adhesive, and photoswitch material | 柯尼卡美能达株式会社 | 2022-04-22 | — | — | CN | disclosed |
| EP-2245038-B1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2018-11-07 | — | — | EP | disclosed |
| EP-1478653-B1 | MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2014-07-02 | — | — | EP | disclosed |
| US-8410065-B2 | Macrolides and their use | BASILEA PHARMACEUTICA AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-20110053876-A1 | MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2245038-A1 | NEW MACROLIDES AND THEIR USE | Basilea Pharmaceutica AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106419-A1 | NEW MACROLIDES AND THEIR USE | BASILEA PHARMACEUTICA AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| US-6727229-B2 | MACROLIDE ANTIBIOTICS PLAY A THERAPEUTICALLY IMPORTANT ROLE, PARTICULARLY WITH THE EMERGENCE OF NEW PATHOGENS | ENANTA PHARMACEUTICALS, INC. | 2004-04-27 | — | — | US | disclosed |
| US-6720308-B1 | Anhydrolide derivatives having antibacterial activity | ENANTA PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-20040038915-A1 | NOVEL 11,12-SUBSTITUTED LACTONE KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | ENANTA PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
| US-20030212011-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG (CH) | 2003-11-13 | — | — | US | disclosed |
| US-20030199459-A1 | Macrolides with antibacterial activity | BASILEA PHARMACEUTICA AG, A SWISS COMPANY (CH) | 2003-10-23 | — | — | US | disclosed |
| EP-1313751-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | Basilea Pharmaceutica AG (CH) | 2003-05-28 | — | — | EP | disclosed |
| WO-2002016380-A1 | NEW MACROLIDES WITH ANTIBACTERIAL ACTIVITY | BASILEA PHARMACEUTICA AG (CH) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053876-A1 | MACROLIDES AND THEIR USE | PDE4A, PDE12, PDE4B | ADORA2A 2894/4885ADORA1 1579/4885ADORA2B 2198/4885 |
| US-20030212011-A1 | Macrolides with antibacterial activity | MRPL21, RPS21, MRPS18A | ADORA2A 4653/4885ADORA1 3267/4885ADORA2B 4756/4885 |
| US-20040038915-A1 | NOVEL 11,12-SUBSTITUTED LACTONE KETOLIDE DERIVATIVES HAVING ANTIBACTERIAL ACTIVITY | CYP51A1, SI, VIP | ADORA2A 4398/4885ADORA1 2991/4885ADORA2B 4373/4885 |
| US-20030199459-A1 | Macrolides with antibacterial activity | MRPL21, MRPS22, MRPL12 | ADORA2A 4404/4885ADORA1 3037/4885ADORA2B 4398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.